CareFusion 213 LLC Initiates Class II Recall of BD ChloraPrep Swabsticks Due to Sterility Concerns
CareFusion 213 LLC has initiated a Class II recall (D-0243-2026) for 106,400 units of BD ChloraPrep Triple Swabsticks from its El Paso, TX facility. This critical action, driven by a lack of assurance of sterility, impacts nationwide distribution. Procurement and regulatory teams must immediately assess inventory, evaluate alternative sourcing for chlorhexidine gluconate and isopropyl alcohol products, and reinforce supplier quality oversight to mitigate patient safety risks.
FDA Mandates Class II Recall for CareFusion 213 LLC's BD ChloraPrep Swabsticks: Sterility Compromise Identified
CareFusion 213 LLC has initiated a voluntary, firm-initiated Class II recall, designated D-0243-2026, for 106,400 units of its BD ChloraPrep™ Triple Swabsticks. This critical action, reported on January 7, 2026, stems from a lack of assurance of sterility for the product, specifically Lot #: 5086623, which carries an expiration date of March 31, 2028. The affected product, a 5.25 mL applicator containing Chlorhexidine gluconate (CHG), 2% w/v, and Isopropyl alcohol (IPA), 70% v/v, is manufactured at the company's El Paso, TX facility (postal code 79912-8000) and distributed nationwide within the United States. The product is identified under NDA021555 and NDC 54365-401-29. For procurement directors and supply chain VPs, this means an immediate need to quarantine any existing inventory of Lot #: 5086623. The absence of sterility assurance for a pre-operative skin antiseptic like BD ChloraPrep Swabsticks presents a direct patient safety risk, potentially leading to surgical site infections or other adverse events. Regulatory affairs heads must ensure internal compliance teams are fully aware of this Class II classification, which indicates that use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Business development executives should assess the competitive landscape for similar antiseptic products as this recall unfolds.
Critical Supply Chain Disruption: Assessing the Impact of ChloraPrep Sterility Failure on Healthcare Operations
The recall of 106,400 units of BD ChloraPrep Triple Swabsticks by CareFusion 213 LLC poses a significant, albeit localized, disruption to the supply chain for essential pre-operative antiseptics across the United States. Chlorhexidine gluconate and Isopropyl alcohol are frontline agents for skin preparation before invasive procedures, crucial for infection prevention in hospitals, clinics, and surgical centers. A Class II recall due to sterility concerns for such a widely distributed product, even if limited to a single lot, necessitates immediate action from healthcare providers to prevent compromised patient outcomes. For procurement directors, the immediate challenge is securing alternative supplies to maintain continuity of care. This may involve expedited sourcing, potentially at higher costs, and rapid qualification of new product lots or alternative manufacturers. Supply chain VPs must evaluate their inventory management systems to ensure swift identification and segregation of affected products, minimizing operational downtime. Regulatory affairs heads should be prepared to address internal and external inquiries regarding product safety and compliance. Business development executives should monitor market shifts, as this event could create opportunities for competitors offering similar sterile antiseptic solutions, such as other chlorhexidine gluconate and isopropyl alcohol formulations, to capture market share.
Escalating Sterility Concerns: Broader Regulatory Scrutiny and Industry-Wide Compliance Imperatives
The CareFusion 213 LLC recall is not an isolated incident but rather indicative of a broader trend of heightened regulatory scrutiny on sterility assurance within the pharmaceutical and medical device sectors. Recent parallel events underscore this imperative: Essential Wellness Pharma faced a Class II recall for its Progesterone Injection in June 2026 due to sterility assurance failures, and Spectra Medical Devices encountered a similar Class II recall for its Lidocaine HCl Injection around the same time for sterility deficiencies. These incidents collectively signal that the FDA is intensifying its focus on manufacturers' quality control systems, particularly concerning sterile products. For regulatory affairs heads, this trend mandates a proactive review of all sterility assurance protocols, environmental monitoring programs, and aseptic processing validations across their organizations and supply networks. Procurement directors must integrate these heightened expectations into their supplier qualification and audit processes, demanding robust data on sterility testing and manufacturing controls. Supply chain VPs should recognize that a failure in sterility assurance, regardless of product type, can trigger widespread recalls, impacting product availability and brand reputation. Business development executives should anticipate that demonstrating superior quality and compliance will become an even more critical differentiator in securing new contracts and maintaining market trust.
Fortifying Procurement Strategies: Building Resilience Against Sterility-Related Supply Chain Vulnerabilities
In light of the CareFusion 213 LLC recall and broader industry sterility challenges, procurement teams must strategically fortify their supply chains to mitigate future disruptions. Relying on a single source for critical sterile products like chlorhexidine gluconate and isopropyl alcohol applicators introduces unacceptable risk. Diversifying the supplier base, even for seemingly commoditized items, is paramount. This involves identifying and rigorously qualifying multiple manufacturers, assessing their facilities, quality management systems, and regulatory compliance history. Procurement directors should prioritize suppliers with robust sterility assurance programs, transparent quality data, and a proven track record of FDA compliance. Implementing a multi-sourcing strategy not only reduces dependence on any single entity but also fosters competitive pricing and ensures continuity of supply during unforeseen events. Supply chain VPs must integrate these risk mitigation strategies into their overall supply chain resilience frameworks, including contingency planning for product shortages. Business development executives should recognize that companies demonstrating resilient supply chains and impeccable quality control will gain a significant competitive advantage, particularly in sensitive healthcare markets where patient safety is non-negotiable. This proactive approach minimizes the commercial impact of recalls and safeguards patient care.
CareFusion 213 LLC's Remediation Path: Navigating Regulatory Expectations and Market Repercussions
The Class II recall of BD ChloraPrep Triple Swabsticks by CareFusion 213 LLC is currently ongoing, signaling that the company is actively working to address the identified sterility assurance deficiencies under FDA oversight. As a firm-initiated voluntary recall, CareFusion 213 LLC is responsible for investigating the root cause of the sterility lapse, implementing comprehensive corrective and preventive actions (CAPA), and ensuring effective communication with affected customers and distributors. The FDA will closely monitor these remediation efforts, which typically include detailed investigations into manufacturing processes, environmental controls, and quality testing protocols at the El Paso, TX facility. For regulatory affairs heads, understanding the FDA's expectations for thorough root cause analysis and robust CAPA implementation is crucial. Failure to adequately address the underlying issues could lead to further regulatory actions, including potential Warning Letters or increased inspection frequency. Procurement directors should monitor CareFusion 213 LLC's progress and communications closely, as the long-term viability of this supplier for critical sterile products will depend on their ability to restore full confidence in their quality systems. Business development executives should anticipate potential reputational damage and market share erosion for CareFusion 213 LLC, creating opportunities for competitors to expand their presence with demonstrably reliable sterile antiseptic offerings.